Santos FN et al., 2015-10-20: Cochrane review of chemotherapy in people over 70 with advanced NSCLC, chiefly platinum versus non-platinum regimens. It finds a survival gain for platinum combinations that must be weighed against more major adverse events, and only low-quality evidence that non-platinum combinations and single agents are equivalent.
In people over the age of 70 with advanced NSCLC who do not have significant co-morbidities, increased survival with platinum combination therapy needs to be balanced against higher risk of major adverse events
Abstract (AUTHORS' CONCLUSIONS)
Santos FN et al., 2015-10-20: Cochrane review of chemotherapy in people over 70 with advanced NSCLC, chiefly platinum versus non-platinum regimens. It finds a survival gain for platinum combinations that must be weighed against more major adverse events, and only low-quality evidence that non-platinum combinations and single agents are equivalent. Funder: internal source, Brazilian Cochrane Center; 'No sources of support supplied' external. Conflicts: three authors none; Fabio N Santos declares lecture payments from Roche, Merck Sharp & Dohme and Bristol-Myers Squibb for advanced melanoma talks and travel support from Pfizer – disclosed, not recused. Drugs: platinum doublets vs non-platinum/single agents; makers not named. Comparator: non-platinum chemotherapy (not placebo). PMC6759539. Study type: review.
